Navigation Links
PAR in Medical Technology

Spherix Reports First Quarter 2009 Earnings

...ockholders' equity Preferred stock, $0.01 par value, 2,000,000 shares authorized; ... - - Common stock, $0.005 par value, 50,000,000 shares authorized; ... 72,188 Paid-in capital in excess of par value 27,610,426 27,602,486 Treasury s...

Bionovo Announces First Quarter 2009 Highlights and Financial Results

...d contingencies Shareholders' equity: Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued and outs...ding - - Common stock $0.0001 par value, 190,000,000 shares authorized, 76,363,101 and 76,3...

Strativa Pharmaceuticals Provides Product Pipeline Update

... products division of a wholly owned subsidiary of par Pharmaceutical Companies, Inc. (NYSE: PRX ), tod...aceuticals is the proprietary products division of par Pharmaceutical, Inc. Strativa is committed to deve...ease visit www.strativapharma.com . About par Pharmaceutical ...

Elbow Ligament Reconstruction Appears Not to Affect Future Professional Advancement in Baseball

...it is heartening to see that the procedure can be successful in allowing future professional athletes to the reach the highest level of competition on par with their peers," said Carolan. The American Orthopaedic Society for Sports Medicine (AOSSM) is a world leader in sports medicine education, res...

Pharmasset Reports Fiscal Year End 2008 Financial Results

...bilities 33,794,724 16,908,073 COMMITMENTS & CONTINGENCIES STOCKHOLDERS' EQUITY Common Stock, $0.001 par value, 100,000,000 shares authorized, 23,340,498 and 21,232,991 shares issued and outstanding at September 30,...

Alfacell Provides ONCONASE(R) NDA Submission Update

...iple molecular mechanisms of action. Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with Megapharm Ltd. for Israel, BL&H Co. Ltd....

SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results

...ckholders' Equity Preferred stock, authorized 5,000,000 shares, $.01 par value, none issued or outstanding - - Common stock, authorized 100,000,000 shares, $.001 par value, 41,130,270 and 40,991,385 issued and outstanding as of Septe...

FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A

...FS is an effective prophylactic FVIII replacement product has 'jump started' the standard of hemophilia care in the United States so that it is now on par with other developed countries, especially those in Western and Northern Europe." The FDA approval of Kogenate(R) FS for routine prophylaxis in chil...

Pharmasset Reports Financial Results for Quarter Ended June 30, 2008

...45 16,908,073 -------------------------- COMMITMENTS STOCKHOLDERS' EQUITY Common Stock, $0.001 par value, 100,000,000 shares authorized, 21,751,503 and 21,232,991 shares issued and outstanding at June 30, 2008 (unaudited) and September 30, 200...

MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development

...uding the recently announced licensing of our thin film formulation of ondansetron, an anti-emetic therapy, to Strativa Pharmaceuticals, a division of par Pharmaceuticals. Our expectation is to partner our PharmFilm(R) escitalopram oxalate product with a pharmaceutical company that is competitively posit...

Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines

...ia multiple molecular mechanisms of action. Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with BL&H Co. Ltd. for Korea, Taiwan and Hong Kong...

Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel

...ia multiple molecular mechanisms of action. Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with BL&H Co. Ltd. for Korea, Taiwan and Hong Kong...

Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial

...rmaceuticals, the proprietary products division of par Pharmaceutical Companies, Inc. (NYSE: PRX ) today...ase visit http://www.strativapharma.com . About par Pharmaceutical par Pharmaceutical, Inc. develops, manufactures and ma...

Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial

...completed by the end of calendar year 2008. Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with BL&H Co. Ltd. for Korea, Taiwan and Hong Kong...

Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis

...rmaceuticals, the proprietary products division of par Pharmaceutical Companies, Inc. (NYSE: PRX ) today...gredient at the site of infection. In July 2007, par Pharmaceutical, Inc. entered into an exclusive licensing agreement under which par received commercialization rights in the U.S. to B...

Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine

...elopment for this target market. Therefore, the Company will direct its resources to concentrate on other drug programs. Immtech's licensing partners, par Pharmaceutical Companies, Inc. and BioAlliance Pharma SA, remain in full support of the Company. Immtech was informed in late December 2007 that a s...

Pharmasset Reports First Fiscal Quarter 2008 Financial Results

... 16,908,073 ------------------------------ COMMITMENTS STOCKHOLDER'S EQUITY Common Stock, $0.001 par value, 100,000,000 shares authorized, 21,288,614 and 21,232,991 shares issued and outstanding at December 31, 2007 and September 30, 2007, r...

Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference

... second-generation polymerase inhibitor, IDX184, delivered multi-log viral load reductions in HCV genotype-1 infected chimpanzees in just 4 days -- on par with the antiviral activity reported to date from protease inhibitors currently in development." Sommadossi continued, "In 2008, we look forward to ...

Immtech Reports Fiscal Second Quarter 2008 Results

...can sleeping sickness trial. During the three-month period ended September 30, 2007, several significant milestones were achieved. In addition to the par Pharmaceutical agreement, Immtech received orphan drug status from the USFDA for pafuramidine to treat malaria and African sleeping sickness, added a ...

Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results

...itments and contingencies Stockholders' equity: Preferred stock, $0.001 par value 5,000,000 shares authorized at September 30, 2007 and Decembe... 31, 2006 - - Common stock, $0.001 par value: Authorized shares, 75,000,000 at September 30, 2007 and D...

Chinese SFDA Grants Immtech Fast Track Status

...entered into an exclusive licensing agreement with par Pharmaceutical Companies, Inc. (NYSE: PRX ) under which par will receive commercialization rights in the U.S. ...lease visit http://www.immtechpharma.com . About par Pharmaceutical Companies, Inc. ...

Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate

...estors purchased 23,605,551 Units ("Units") at a price of $1.08 per Unit with each Unit consisting of four shares of the Company's common stock, $0.01 par value, and a warrant to purchase one share of common stock. 13,842,590 of the Units were purchased for cash, with the balance of 9,962,961 Units issue...

Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results

...e preferred stock - - Common stock 6,190 6,149 Capital in excess of par 329,237 327,228 Treasury stock (5,321) (5,321) Accumulated deficit ...

Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)

...tablets. As previously announced, in November 2006 par entered into a supply and distribution agreement w...traZeneca's TOPROL-XL(R) extended release tablets. par began shipping 25 mg tablets of generic Toprol-XL ...king metoprolol succinate extended release. About par ...

DVT Awareness Survey Findings: Heart and Respiratory Patients

...s know only as much about it as the general population. * 52% of heart/respiratory patients have some knowledge about DVT -- on par with the general population (51%). * 40% of heart/respiratory patients have heard or read about DVT recently, the same percentage as...
Other Tags
(Date:9/15/2014)... the Department of Science and Technology in Society in ... Virginia Tech, has won a 2014 National Science Foundation ... and problems of creating a global nuclear emergency response ... Nuclear Power Plant in March 2011 was a turning ... Schmid said. Three of the plant,s six nuclear reactors ...
(Date:9/15/2014)... wild, domesticated, and domesticated-wild hybridized populations of ... that within 5 to 11 generations, selection ... populations that hybridized with domesticated populations. , ... evidence that natural selection, over time, removes ... as a result of increased genetic diversity. ...
(Date:9/15/2014)... in West Africa, which has claimed more than 2000 ... of the molecular biology of the virus that could ... drugs to treat or prevent Ebola hemorrhagic fever. Now, ... under the leadership of Dr Dan Engel, a ... has obtained the crystal structure of a key protein ...
Breaking Biology News(10 mins):'Nuclear disasters don't respect national boundaries' 2Protein secrets of Ebola virus 2
(Date:9/15/2014)... one out of every 40 individuals in the United States ... atrophy (SMA), a neurodegenerative disease that causes muscles to weaken ... made a recent breakthrough with the development of a new ... the disease. In April, a patent was filed for the ... is using to fight SMA is to ,repress the repressor," ...
(Date:9/15/2014)... September 15, 2014 In order to ... medicine often act conjointly to quantify, define and model ... become an integral part of medical care. , The ... the studies conducted by the non-profit Institute of BioAcoustic ... demonstrated that math can be much more than a ...
(Date:9/15/2014)... Dennis Thompson ... News) -- The severe respiratory virus believed to have ... states has now spread to the Northeast, health officials ... confirmed on Friday more than a dozen cases of ... for children with asthma. And on Saturday, the ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 As ... end of its first full year, there are ... maturing; especially in the evolution of its marketing ... approach being taken by Denver's Kindman, one of ... and distributors. , Kindman has pioneered the first-ever ...
(Date:9/15/2014)... September 15, 2014 As Risperdal lawsuits ... Bernstein Liebhard LLP notes that a new study has ... curbing aggression in children with ADHD when it is ... in behavioral management techniques. According to a report from ... and aggression problems, half of whom took Concerta, a ...
Breaking Medicine News(10 mins):Health News:Researcher develops and proves effectiveness of new drug for spinal muscular atrophy 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 3Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 3Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 2Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 2Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 4
Other Contents